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Alzheimer’s disease (AD) is the most common form of dementia. At the diagnostic stage, the AD brain is
characterized by the accumulation of extracellular amyloid plaques, intracellular neurofibrillary tangles and neuronal
loss. Despite the large variety of therapeutic approaches, this condition remains incurable, since at the time of
clinical diagnosis, the brain has already suffered irreversible and extensive damage. In recent years, it has become
evident that AD starts decades prior to its clinical presentation. In this regard, transgenic animal models can shed
much light on the mechanisms underlying this “pre-clinical” stage, enabling the identification and validation of new
therapeutic targets. This paper summarizes the formidable efforts to create models mimicking the various aspects
of AD pathology in the rat. Transgenic rat models offer distinctive advantages over mice. Rats are physiologically,
genetically and morphologically closer to humans. More importantly, the rat has a well-characterized, rich
behavioral display. Consequently, rat models of AD should allow a more sophisticated and accurate assessment of
the impact of pathology and novel therapeutics on cognitive outcomes.
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Despite important advances in our understanding of
the molecular basis of Alzheimer’s disease (AD) neuro-
pathology and the large variety of novel therapeutic ap-
proaches attempted, this condition remains incurable.
The recent failure of passive immunotherapy clinical trials
(Bapineuzumab and Solanezeumab) best illustrates the
challenges that lay ahead [1]. It seems that the main
obstacle to an effective therapy is that, at the time of
clinical diagnosis, the brain has already suffered extensive
and perhaps irreparable damage.
At the diagnostic stage, the AD brain is characterized by
abundant senile amyloid plaques, formed by extracellular
aggregates of amyloid-beta (Aβ) peptides, and by neurofib-
rillary tangles (NFTs) consisting of intracellular aggregates
of abnormally phosphorylated tau (p-tau) protein (reviewed
in [2-4]). The neurodegenerative changes in the central ner-
vous system (CNS) neurons and synapses ultimately lead to
the progressive cognitive decline characteristic of AD [5].* Correspondence: claudio.cuello@mcgill.ca
1Department of Pharmacology and Therapeutics, McGill University, 3655
Promenade Sir-William-Osler, Room 1325, Montreal, Quebec H3G 1Y6,
Canada
2Department of Anatomy and Cell Biology, McGill University, Montreal,
Quebec H3A 2B2, Canada
Full list of author information is available at the end of the article
© 2013 Do Carmo and Cuello; licensee BioMe
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumThere is also substantive evidence indicating that CNS
pro-inflammatory mechanisms contribute to cognitive
impairment [6,7]. Inflammatory processes in AD have
been classically regarded as an Aβ plaque-induced event,
characterized by activation of microglia and astrocytes
surrounding the plaques [8,9].
In recent years, it has become evident that AD starts
decades prior to its clinical presentation, based on bio-
marker studies in familial and sporadic forms of the
disease [10-12]. Exploring the neuropathology of AD
in such human “pre-clinical” stages is not an easy task.
Transgenic animal models can shed much light on the
many factors impacting or accelerating disease progression.
They can also be of value to identify new biomarkers or
potential new therapeutic targets. Transgenic rat models of
the AD-like pathology offer distinctive advantages, as will
be discussed below.
Transgenic models of AD
Our knowledge of the molecular mechanisms underlying
AD pathogenesis has made a leap forward with the creation
of the first transgenic AD mouse models in the mid 1990s
[13-15]. Based on the identification of the mutations in the
amyloid precursor protein (APP), presenilin 1 (PS1) and
presenilin 2 (PS2) genes involved in the familial forms ofd Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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amyloid accumulation, abnormal tau phosphorylation,
inflammation or behavioral deficits [13-17].
Transgenic mouse models have made an important
contribution to testing the so-called “Amyloid Hypothesis”.
Furthermore, they have played a role in assessing a large
variety of disease-modifying compounds. Given the pro-
gressive and predictable evolution of the pathology, the
use of transgenic models also offers the opportunity to
find reliable biomarkers, crucial in detecting the disease
at the early, “silent”, asymptomatic stage, during which
therapeutic interventions would have much greater pos-
sibilities of success.
Although transgenic mouse models have proven highly
valuable in elucidating the mechanisms involved in AD,
the recent failure of AD immunotherapy highlights the
necessity of developing superior models of the AD path-
ology. The ideal transgenic model should mimic multiple
aspects of the disease including its etiology and a time-
dependent progression of the pathology, involving similar
structures and cells similar to the human pathology. Most
importantly, however, the model should provide reliable,
longitudinal readings about the status of higher brain
function by applying suitable learning and memory tests,
analysis of body fluids, such as cerebrospinal fluid, and
imaging. Such models should be free of confounding
factors such as impairments in visual or motor systems,
which can be falsely interpreted as AD deficits provoked
by nonspecific transgene- or strain-effects.
Advantages of using rats: the rat as a model for AD
Historically, mice were preferred over rats for transgenesis
mainly due to technical reasons. Compared to mice, rat
one-cell embryos have less visible pronuclei and more
flexible plasma and pronuclear membranes, making trans-
gene injection in pronuclei more difficult [18]. The low
survival of embryos following injection also contributes
to making rat transgenesis more demanding and time-
consuming [18]. Additionally, tools for manipulation of the
rat genome are less readily available [19]. Until recently,
embryonic stem (ES) cell-based targeting technology, a
powerful tool allowing gene replacement (knock-in) or
loss of function mutations (knock-out), was not available,
as viable rat ES cells had been difficult to obtain [20].
Despite these drawbacks, rats offer numerous advantages
compared to mice. The rat is physiologically, genetically
and morphologically closer to humans than mice [21-23].
Its larger body and brain size facilitates intrathecal ad-
ministration of drugs, microdialysis, multiple sampling
of cerebrospinal fluid, in vivo electrophysiology, as well
as neurosurgical and neuroimaging procedures [19]. Of
relevance for AD modeling, similarly to humans, the rat
contains 6 isoforms of tau [24], although the ratio of 4R/3R
tau isoforms is different (9:1 in rats; 1:1 in humans). Inaddition, there is good homology between the rat and
human apoE amino acid sequences (73.5% with human
apoE3, 73.9% with apoE4) [25,26]. However, while its
sequence is more similar to apoE4, rat apoE displays the
biophysical behavior of apoE3 [27].
Another major advantage of this species is that it is
behaviorally well characterized. Rats have finer and more
accurate motor coordination than mice and exhibit a
richer behavioral display. They also display a more complex
social behavior. They display juvenile play fighting and
courtship as well as low levels of aggression [28]. Since the
rat is a terrestrial, aquatic and arboreal mammal, it is more
competent and less stressed in water-based navigation
tasks such as the Morris water maze (MWM) [28]. These
behavioral differences may be accounted for by the fact that
rats, like humans, and opposed to mice, have a post-natal
brain development that would lead to a greater number of
synapses and a more complex synaptic organization [28].
Consequently, rat models of AD should allow a more so-
phisticated characterization at the behavioral level and thus
enable a more accurate assessment of the impact of the
pathology on cognitive outcomes. They should also enable
a better assessment of the effects of potential therapeutics
on cognition in longitudinal studies.
Based on these advantages, rats are increasingly and
successfully used to mimic key pathological hallmarks
of neurodegenerative diseases including Alzheimer’s
(as discussed in this review), Parkinson’s (PD) [29-31],
Huntington’s (HD) [32], amyotrophic lateral sclerosis
[33] and tauopathies [34,35].
Importantly, it has been reported that some transgenic
rat models offer a more accurate representation of the
human disease compared to mice bearing the same
transgene. This has been exemplified in hypertension
[36] and atherosclerosis [37], as well as in models of
neurodegenerative diseases. Thus, mouse models of HD
can only mimic juvenile HD pathological changes whereas
HD transgenic rats allow study of the common adult type
of the disease [32]. Also, no significant loss of dopamin-
ergic neurons is observed in the human alpha-synuclein
transgenic mouse model of PD, but severe loss of the dopa-
minergic integrity is reported in human alpha-synuclein
transgenic rats [31].
Early rat models of AD
Rats have played a prominent role in the modeling of
AD, well before the advent of transgenesis. However,
most of the models summarized in this section do not
represent accurate model systems for AD as they do not
exhibit neuritic plaques, NFTs or neuron loss. This is the
case, for example, in aged rats, which reflect only some
aspects of human aging, such as learning and memory
impairments and moderate deficits in cortical cholinergic
and dopaminergic function [38-40].
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extensively used, particularly to test the cholinergic hypoth-
esis of AD. This hypothesis states that CNS cholinergic
deficits in elderly adults and demented patients are the
main factors responsible for their cognitive impairments
[41-43], and has led to the well-established, symptomatic,
anticholinesterase therapies (for review see [44]).
A large variety of compounds have been used to induce
AD-like cortical cholinergic neuronal loss with varying
degrees of specificity. These include the relatively non-
specific scopolamine [45,46] and the p75NTR-specific
immunotoxin for cholinergic neurons, 192-IgG-saporin
[47,48]. Several rat lesion models have been used, and
include models of brain trauma [49], bilateral transection
of the hippocampal fimbria-fornix [50], ovariectomy [51]
and hyperthermia on the post-ischemic brain [52], the last
creating AD-like pathology [52].
The finding that Aβ is central to the development of
plaques [53] and is neurotoxic [54] has led to studies
investigating the impact of Aβ on brain function in vivo.
However, although cerebral infusion of Aβ in naïve rats
can recapitulate some key features of human AD including
cholinergic dysfunction, Aβ deposits, ventricular en-
largement, neuron loss and behavior deficits, it can not
simulate the progressive neurodegeneration characteristic
of AD [55-58]. In addition, there is great inconsistency
between Aβ infusion models, likely due to differences in
methodology such as identity, type (fresh, presumably
oligomeric, versus fibrillar forms) and the concentration
of peptide administered, duration of the treatment and site
of infusion. Therefore, while such models might be of
value to examine specific aspects of the amyloid path-
ology, they fail to reproduce the full spectrum of AD
neuropathological hallmarks.
Virus-mediated rat models of AD
More recently, the advance of virus-mediated gene trans-
fer technology has allowed for the expression of human
APP (hAPP)695 bearing the Swedish mutation in the adult
rat hippocampus. This induced Aβ42 immunoreactivity
and learning deficits in the MWM up to 12 months post-
injection. However, the injection did not lead to Aβ plaque
deposition, gliosis or neural loss [59]. Virally-mediated
gene transfer of human Aβ42 and Aβ40 peptides bearing
the British mutation into the hippocampus of adult Wistar
rats has also helped to establish the contribution of each
Aβ species in AD [60].
Transgenic rat models of AD
Since the early 2000s, a wide array of transgenic rats has
been created based on the expression of human genes
relevant for early-onset familial AD such as wild-type or
mutated APP and mutated PS1. These models offer a
large heterogeneity in their phenotype, which arises fromseveral factors. First, the expression of these transgenes
is controlled by different neuronal promoters resulting
in varying expression strengths and patterns. In addition,
these models were produced and stabilized in both inbred
(Lewis and Fischer-344) or outbred (Sprague Dawley and
Wistar) genetic backgrounds [18]. It is now well established
that genetic background has a great influence on pathogen-
esis. For example, it was demonstrated that rat strain
SHR72 expressing human truncated tau (151–391, 4R)
under the control of the Thy1 promoter (Table 1) displayed
different NFT load and neuroinflammation markers de-
pending on the background in which it was stabilized [61].
Differences in expression strength can also result from the
method used to introduce the transgene in fertilized eggs
(pronuclear injection of DNA or lentiviral delivery). Most
importantly, differences in phenotypes may be explained
by the introduction of single, double or triple transgenes.
Rat models of amyloid pathology devoid of plaques
The earliest transgenic rat models of AD showed accumu-
lation of intracellular Aβ (iAβ) but no senile plaques. It was
suggested that this was due to inadequate Aβ levels, since
higher concentrations are required to initiate the deposition
process. Some of these models however, did display synap-
tic dysfunction (LTP and behavior) supporting the view that
cognitive deficits are independent of plaque formation but
correlate better with Aβ oligomers and other Aβ species.
Our first attempts to generate rat models of AD failed
to reproduce the classical AD pathological hallmarks
(Table 1) [62-65]. This can be attributed to moderate
levels of APP gene expression. However, UKUR25 and
UKUR28 transgenic rat strains showed an important ac-
cumulation of intracellular Aβ (iAβ)-immunoreactive
material in pyramidal neurons of the neocortex and in
CA2 and CA3 regions of the hippocampus. These models
significantly contributed in supporting the role of iAβ in
the amyloid cascade at the early, pre-plaque phase of the
amyloid pathology. Indeed, they confirmed in vivo that the
accumulation of iAβ material, in the absence of plaques,
induces deregulated ERK2 activation [62,63] as previously
demonstrated in vitro [66,67]. Furthermore, they also
demonstrate that iAβ is sufficient to trigger the initial
steps of the tau-phosphorylation cascade, learning impair-
ments in the MWM task [62,63], significant changes in
the hippocampal proteome, particularly in synaptic proteins
implicated in learning and memory formation [65] and
morphological alterations in the Golgi apparatus, lysosomes
and lipofuscin bodies [64].
Intracellular iAβ accumulation was observed in other
rat models of amyloid pathology. Similarly to our model,
TgAPPswe rats do not develop extracellular plaques or
NFTs up to 18 months of age [68]. These rats show a mild
increase in APP mRNA (56.8% at 12 months). In contrast
with UKUR25, these rats perform better at 6 and 12
Table 1 Transgenic rat models of Alzheimer’s disease
Name Transgene Background Amyloid pathology Tau pathology Other References
UKUR28 hAPP751 Swe, IndPDGF
promoter
Wistar (outbred) iAβ in cortex and hippocampus
from 6 moNo plaques
N/A Increased pERK2 [62,63]
UKUR25 hAPP751 Swe, Ind Human
PS1 (M146L) PDGF promoter
Wistar (outbred) iAβ in cortex and hippocampus
from 6 moNo plaques
Increased ptau (PHF-1) at






TgAPPswe hAPP751 Swe, PDGF promoter Fisher-344 (inbred) Increased APP mRNA (56%) and
Aβ-40 and Aβ-42 peptides, no
plaques
N/A Better cognitive performance in
MWM and STFP
[68]






at 15 moFew diffuse plaques
Increased ptau (PHF-1) at
15 mo, no tangles.
Impairment in MWM and
open-field
[75,76]
hAPP695 hAPP695 wild-type, UbiquitinC
promoter
Wistar (outbred) Increased APP/ Aβ levels (2 fold)
in cortex and hippocampus no
plaques
N/A Smaller infarct volume impairment
in MWM and BWT after MCAO
[72]
APP21APP31 hAPP695 Swe, Ind, UbiquitinC
promoter Lentiviral delivery
Fisher-344 (inbred) Increased APP products and
APP mRNA in brain (2.9 fold),
kidneys and lungs Increased





hAPP695 Swe, Rat synapsin I
promoterhAPP695 Swe,
Lon, PDGFβ promoter Human




Mostly diffuse plaques Few
compact plaques in
hippocampus. No vascular
Aβ depositsAβ load confirmed
with (F-18) FDDNP microPET
Increased ptau (AT8, PHF-1),
no tangles
Impairment in LTP and in MWM
performance Activation of




McGill-R-Thy1-APP hAPP751 Swe, Ind, Mouse
Thy1.2 promoter
Wistar (outbred) Progressive accumulation of
iAβ in cortex and hippocampus
from 1 week post-natalAβ
plaques starting at 6-9 mo






TgF344-AD hAPP695 Swe, Human
PS1ΔE9 Mouse PrP
promoter
Fisher-344 (inbred) Progressive accumulation of





Deficits in open-field, NOR, BM
Presence of dystrophic neurites,
activated astrocytes and microglia
around plaques. Neuronal loss
[91]
SHR72 and SHR318 Human tau truncated
(151-391, 4R) Mouse
Thy1 promoter
SHR (inbred) N/A Increased ptau (AT8)Tangles
in brainstem
Deficits in MWM and BWT Impaired
reflex responses no neuronal loss
in brain, axonal damage in the
brain stem and spinal cord,
decreased lifespan
[35,95,96]
SHR24 Human tau truncated
(151-391, 3R) Mouse
Thy1 promoter
SHR (inbred) N/A Increased ptau (DC11 and others)
Tangles in cortex
No neuronal loss in cortex and
hippocampus, decreased lifespan
[97]
BM Barnes maze, BWT beam walking test, IHC immunohistochemistry, MCAO middle cerebral artery occlusion, mo months-old, MRS magnetic resonance spectroscopy, MWM Morris water maze, N/A information not
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MWM and the social transmission of food preference task
when compared with non-transgenic animals. This dis-
crepancy can be explained by differences in the genetic
background and the transgene expressed (Table 1), as
TgAPPswe rats do not carry the APP Indiana and the
PS1 Finn mutations, which could result in lower iAβ levels.
Accordingly, the authors suggest a dose-dependent effect
of APP, which would play a role in normal learning and
memory processes at low doses but would lead to neurode-
generation and cognitive decline at higher doses [68].
Models expressing wild-type or mutated hAPP isoform
695 (hAPP695) have also been attempted. This choice is
justified, as it is regarded as the isoform preferentially
expressed by neurons. In addition, it was reported that
there is a selective loss of APP695 transcripts in the brain
of AD-affected patients [69]. However, it has been shown
in vitro and in transgenic mouse models that overexpres-
sion of hAPP751 causes more AD-like pathology and
cognitive impairments than hAPP695 [70,71].
Trangenesis with wild-type hAPP695 results in a
two-fold increase of APP/Aβ fragments in cortex and
hippocampus compared to non-transgenic animals, lead-
ing to behavioral impairments after middle cerebral artery
occlusion [72]. Higher levels of APP expression (2.9 fold
more APP mRNA) were first achieved in the brain of
APP21 and APP31 inbred models which were created by
injecting recombinant lentivirus carrying the hAPP695
with the Swedish and Indiana mutations into zygotes
(Table 1) [73]. These models have substantial quantities of
Aβ40 and 42 in serum, and especially so in homozygous
animals. Circulating Aβ most likely does not arise from
the brain, as the models also express high levels of APP
mRNA in the kidneys, heart and lungs. Desspite of the
high levels of human APP in neurons of the cortex and
hippocampus, they do not develop extracellular deposits
of Aβ [74]. However, senile plaques and cerebral Aβ
angiopathy can be observed 9 months after the cerebral
injection of dilute brain extracts from AD patients into
APP21 animals, suggesting that Aβ deposition can be
exogenously seeded if the host expresses human Aβ [74].
A third rat model expressing hAPP695 with the Swedish
mutation (Table 1) has shown an accumulation of iAβ
in neurons of the cortex, hippocampus and cerebellum
and an increased amount of soluble Aβ material. At 9
months old, Tg6590 exhibits impaired spatial learning
in the MWM and altered spontaneous activity in the open-
field [75]. In addition, magnetic resonance imaging (MRI)
suggests a tendency towards enlargement of the lateral
ventricles at 11 months old [75]. At 15 months of age,
these rats show Aβ cerebrovascular deposits, rare diffuse
plaques, and tau hyperphosphorylation at PHF-1 site
without the formation of mature plaques or NFTs even
by the age of 22 months [75,76].Rat models of amyloid pathology with mature plaques
The first model to develop amyloid plaques was achieved
in homozygous double transgenic rats Tg478/Tg1116
expressing hAPP695 carrying the Swedish and Swedish/
London mutations. These rats show increased APP, Aβ40
and Aβ42 load and developed diffuse plaques by 17–18
months of age [77]. The age of plaque onset was acceler-
ated to 9 months by introducing a third transgene carrying
a human mutated presenilin gene [77,78]. From the age of
9 months-old, PSAPP rats (also named Tg478/Tg1116/
Tg11587) display abundant diffuse plaques in the cortex,
hippocampus, olfactory bulb, thalamus and hypothalamus
but not in the cerebellum or brain-stem (Table 1). How-
ever, only few compact plaques are detectable in the
hippocampus even at 22 months-old and no vascular
Aβ deposits are observed. The progressive accumulation of
Aβ plaques was confirmed with the use of [F-18]FDDNP
micro positron emission tomography [79]. Astrocytic and
light microglial activation and tau hyperphosphorylation is
present around compact plaques. These rats also show
impaired LTP accompanied by progressive behavior defi-
cits in the MWM task, detectable at 7 months of age, in
the absence of plaques. Behavior deficits correlate with
Aβ42 load in the hippocampus. However, these rats lack
neurofibrillary pathology or neuronal loss [78]. Its use as an
efficient AD model is also hampered by a tendency towards
premature death related to kidney disease, hypertension
and immunosuppression, which are likely a consequence of
the genetic disturbance caused by the presence of the triple
transgenes [80].
The McGill-R-Thy1-APP rat model is the only model
able to reproduce extensive AD-like amyloid pathology
with a single transgene (Figure 1) [81]. This model ex-
presses the hAPP751, bearing the Swedish and Indiana
mutations under the control of the murine Thy1.2 pro-
moter. In the McGill-R-Thy1-APP transgenic rat, a single
transgene is able to produce human APP expression specif-
ically in AD-relevant areas of the brain without cerebellar
and peripheral tissue expression. The presence of a single
transgene with a low copy number makes of this rat the
least genetically aggressive AD transgenic model developed
so far.
McGill-R-Thy1-APP rats display iAβ as soon as one
week post natal in the cortex and hippocampus in both
hemi and homozygous animals. The oligomeric nature of
the iAβ material was confirmed using the NU-1 monoclo-
nal antibody that specifically recognizes soluble aggregates
of Aβ [82]. The pathology is dose-dependent as, in homo-
zygous animals, iAβ accumulation leads to progressive
neuritic plaque deposition starting from 6–9 months old.
Hemizygous rats develop no or very few plaques at much
later stages. The anatomical spreading of plaques coin-
cides with that observed in human AD, starting from the
subiculum and expanding to the entorhinal cortex and
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Figure 1 The McGill-R-Thy1-APP transgenic rat phenotype. (A) The McGill-R-Thy1-APP transgenic rat expresses the human APP751, bearing
the Swedish and Indiana mutations under the control of the murine Thy1.2 promoter. Its phenotype is fairly similar to the human pathology
reported in AD and MCI. (B) We observe intraneuronal Aβ accumulation starting at 1 week post-natal, as determined with our murine
monoclonal antibody (McSA1) against the N-terminus of the Aβ peptide. The development of plaques follows the same anatomical sequence as
in humans. Mature amyloid plaques are Thioflavin S-positive (C) and are surrounded by activated microglia as observed with MHCII- (brown) and
Aβ-specific antibodies (McSA1-blue) and also with Iba-1(blue) and McSA1(blue) (D). Plaques are also accompanied by dystrophic neurites (E) and
astrogliosis (GFAP-blue, McSA1-green) (F). (G) These rats already show learning deficits in the Morris water maze task at the pre-plaque stage
(3 months old) and these deficits progress with amyloid accumulation. Images adapted from [81] with the publisher’s permission and from [83].
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includes the presence of transmitter-specific dystrophic
neurites (Figure 1) [81]. Moreover, we have recently
observed a recruitment of microglia towards iAβ-
burdened hippocampal neurons and a remarkable pre-plaque astrogliosis [83]. It is of significance that the
McGill-R-Thy1-APP rat presents progressive behavior
impairments in the MWM starting at 3 months of age
while no amyloid plaques are yet present. The deficits
are transgene-dose-dependent and they correlate with
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likely corresponding to a combination of Aβ trimers and
the APP C-terminal fragment, C99 [81]. This observation
reinforces the hypothesis on the impact of oligomeric iAβ
in cognition [84].
These rats were also used to study metabolite levels
by magnetic resonance spectroscopy in the dorsal hippo-
campus and frontal cortex. The findings demonstrate
complex metabolite alterations during the progression
of the amyloid pathology, different from those observed
during normal aging [85]. MRI imaging on these rats
also showed marked brain shrinkage, which is more evident
for the hippocampal complex and resting-state connectivity
impairment [86-88]. Consistent with these observations,
McGill-R-Thy1-APP rats display impairments in firing rates
for place discrimination of spatial context [89] and a
very compelling in vivo impairment in hippocampal
LTP formation at preplaque stages [90].
More recently, a bigenic TgF344-AD rat has been
reported (Table 1) [91]. These rats express hAPP695,
with the Swedish mutation, and PS1ΔE9 under the control
of the strong murine PrP promoter. These rats demon-
strate strong age-dependent accumulation of iAβ, soluble
and insoluble Aβ40 and Aβ42 peptides and thioflavin-
positive amyloid plaques. The amyloidosis is associated
with hyperactivity in the open-field as well as age-
dependent deficits in spatial learning and memory as
assessed with the novel object recognition and the
Barnes maze tasks. Surprisingly, as it was never seen
before in other transgenic rat models of AD and even
in transgenic AD mouse models expressing APP and
PS1 mutations, by 16 months of age these rats present
Gallyas-positive structures resembling NFTs seen in
human AD. These structures contain p-tau as detected
with several p-tau antibodies. The observed amyloidosis
and tauopathy are accompanied by neuronal loss. These
rats also present glial activation as early as 6 months old,
before appreciable extracellular Aβ deposition [91].
Rat models of tau pathology
Several transgenic mouse models expressing mutated
forms of human tau develop neurofibrillary degeneration
[92,93]. Because the rat contains 6 tau isoforms, as do
humans, rat models of tau pathology were also created
(Table 1) [35,94-97]. Overexpression of human non-
mutated truncated tau encompassing 4 repeat domains
(151–391, 4R) in neurons leads to a hyperphosphorylation
of tau and the development of neurofibrillary degeneration
similar to that reported in AD [35]. Behavior analysis
highlighted a progressive cognitive decline in spatial navi-
gation in MWM, as well as disturbances in sensorimotor
and reflex responses [95]. These impairments correlate
with the progressive accumulation of argyrophilic NFTs
and mature sarcosyl-insoluble tau complexes and extensiveaxonal damage in the brain stem and spinal cord. However,
although hyperphosphorylated tau was observed in cortex
and hippocampus, no neuronal loss or tangles were ob-
served in the brain [95]. These impairments lead to de-
creased lifespan [35,96]. The first rat model developing
progressive NFTs in the cortex expresses a human non-
mutated truncated tau encompassing 3 repeat domains
(151–391, 3R). These rats develop progressive cortical
neurofibrillary degeneration as early as 9 months of age
[97]. Surprisingly, this rat does not show neuronal death
in the cortex, the region with the largest accumulation of
tangles, or the hippocampus, the region presenting the
highest expression of human tau. However, the neurofi-
brillar pathology leads to decreased lifespan. More models
of tau transgenesis are likely to appear in coming years.
Comparison of transgenic rat and mouse models of AD
It has been more complicated to achieve AD-like amyloid
deposition in the brain of transgenic rats than mice. The
elevation of soluble Aβ or the extent of plaque accumula-
tion is often less in rat (Table 1) than in mouse models
expressing similar constructs, resulting in less aggressive
phenotypes. Accordingly, Tg6590 [75,76] (Table 1), fail to
develop mature plaques despite displaying some cognitive
impairments. Conversely, its equivalent in mice, Tg2576,
which expresses hAPP695 bearing the Swedish mutations
under the control of the PrP promoter, presents cognitive
decline accompanied by numerous Aβ plaques [98]. Simi-
larly, TgAPPswe rats show very slight increases in Aβ pep-
tide production with no plaque development [68] while
TgAPP23 mice expressing hAPP751 with the Swedish
mutations under the control of the Thy-1 promoter show
typical plaques by 6 months of age accompanied by
neuritic and synaptic degeneration [99]. Furthermore,
TgCRND8 mice [100] expressing hAPP695 with the
Swedish and Indiana mutations under the control of
the PrP promoter develop early and extensive plaque
deposition by 3 months of age while APP21 and APP31
rats [73,74] never accumulate extracellular amyloid. In
these cases, differences in phenotype might arise from
differences in the promoters used in mice and rats. In sup-
port to this, TgAPP(Sw,V717F) mice [101] and UKUR28
rats [62,63] expressing hAPP751with the Swedish and
Indiana mutations driven by the PDGF promoter have
similar phenotypes despite an absence of Aβ42 and plaque
accumulation.
However, there are other cases where the exact same
construct used in the two species resulted in different
phenotypes indicating that species-specific factors likely
contribute to these phenotype differences. For example,
McGill-Thy1-APP mice [102] and McGill-Thy1-APP rats
[81] expressing exactly the same construct containing
hAPP751 with the Swedish and Indiana mutations under
the control of the Thy1 promoter develop a similar
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(plaques at 4 months) than in the rat (plaques at 6–9
months), the latter needing to be homozygous to develop
plaques. This might be explained by the number of copies
of the transgene inserted in the host DNA. While few
transgene copies are present in McGill rats [81], McGill
mice [102] contain more than 20 copies of the transgene.
Phenotypic differences were also observed in TgF344-AD
rats [91] and Tg-APPswe/PS1dE9 mice [103,104], both
expressing hAPP695 with the Swedish mutations under
PrP regulatory control. These models show extensive and
progressive amyloid pathology accompanied by cognitive
deficits and some tau pathology. However, TgF344-AD
rats have greater abundance of soluble oligomeric Aβ
species. Also, while TgF344-AD rats display NFT-like
structures and frank neuronal loss, these are not observed
in Tg-APPswe/PS1dE9 mice.
Concluding remarks and future directions
Transgenesis in rats offers great potential to decipher
subtle and early aspects of AD pathology. The rat is, in
many aspects, closer to humans than mice. Because of
its predictable and multi-faceted behavioral display, this
species is of great value for accurate cognitive assessment.
The current rat transgenic models, while replicating all as-
pects of the amyloid pathology including inflammation and
the presence of dystrophic neurites, remain incomplete
models as it does not develop “bona fide” human-like
neurofibrillary tangles. Despite these weaknesses, current
transgenic rat models of AD are contributing significantly
to our understanding of processes and mechanisms in-
volved in the disease progression. However, as the available
AD rat models display varying degrees of competence in
recapitulating the characteristics and severity of the
pathology, the choice of the model is crucial for the
investigative objectives. Also, although the CNS of rats
is closer to humans than that of the mouse, the extrapo-
lation of conclusions from rat to humans would require a
measure of caution. These transgenic models are closer to
the pathology elicited in familial AD (both genetically
driven), however, models with a minimal genetic invasive-
ness, such as the McGill-R-Thy1-APP, offer the closest
available analogy to the human sporadic AD pathology.
Despite their obvious limitations, transgenic rat models
will be of great assistance in the search of potential bio-
markers signaling an early, preclinical, pathology and in
the search and validation of novel therapies. From the
experimental point of view, they have already shown to
be of significant advantage for in vivo electrophysiology,
imaging, proteomics, epigenetics and in the future for
optogenetic studies.
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